VRTX · 8-K · 20261102PR000287

Capital Return Program

VERTEX PHARMACEUTICALS INC / MA · 2026-11-02 · Importance 18 · Surprise 14

Vertex used cash during the first nine months of 2026 to repurchase common stock under its share repurchase program. The company reported $9.0 billion of net cash used for the Crinetics acquisition and share repurchases combined, without disclosing the repurchase portion separately. Common shares outstanding were 253.5 million at September 30, 2026, compared with 254.0 million at December 31, 2025. The reported cash decline also reflected the acquisition, partly offset by $4.5 billion of term-loan borrowings and operating cash flows.